¼¼°èÀÇ ±â°ü ½ºÅÙÆ® ½ÃÀå
Tracheal Stents
»óǰÄÚµå : 1769023
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 177 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ±â°ü ½ºÅÙÆ® ½ÃÀåÀº 2030³â±îÁö 2¾ï 1,950¸¸ ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 1¾ï 4,670¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ±â°ü ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº 2024-2030³â CAGR 6.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 2¾ï 1,950¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±Ý¼ÓÀº CAGR7.4%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 1¾ï 5,420¸¸ ´Þ·¯¿¡ À̸¦ Àü¸ÁÀÔ´Ï´Ù. ÇÃ¶ó½ºÆ½ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 6.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,820¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 10.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±â°ü ½ºÅÙÆ® ½ÃÀåÀº 2024³â¿¡´Â 3,820¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ 2024-2030³â°£ CAGR 10.3%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â ¿¹Ãø ½ÃÀå ±Ô¸ð 5,180¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 3.6%¿Í 6.4%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.3%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ±â°ü ½ºÅÙÆ® ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

±â°ü ½ºÅÙÆ®¶õ ¹«¾ùÀ̸ç, ¿Ö ±âµµ °ü¸®¿¡ ÇʼöÀûÀΰ¡?

±â°ü ½ºÅÙÆ®´Â ±â°üÀÌ ¸·È÷°Å³ª Á¼¾ÆÁø ȯÀÚÀÇ ±âµµ¸¦ È®º¸Çϱâ À§ÇØ °í¾ÈµÈ °ü ¸ð¾çÀÇ ÀÇ·á±â±âÀÔ´Ï´Ù. ½Ç¸®ÄÜ, ´ÏƼ³î, ±âŸ »ýü ÀûÇÕ¼º ÇÕ±Ý µîÀÇ Àç·á·Î ¸¸µé¾îÁø ±â°ü ½ºÅÙÆ®´Â Á¾¾ç, ¿Ü»ó, ¿°Áõ, ¼±Ãµ¼º ±âÇü µîÀ¸·Î ÀÎÇØ ±âµµ°¡ Á¼¾ÆÁø °æ¿ì ±â°üÀ» ¾ÈÁ¤½ÃŰ°í °ø±â È帧À» ¹æÇØÇÏÁö ¾Êµµ·Ï Çϱâ À§ÇØ »ç¿ëµË´Ï´Ù. ½ºÅÙÆ®´Â ÀÚ°¡È®ÀåÇü°ú dz¼±È®ÀåÇüÀÌ ÀÖÀ¸¸ç, ȯÀÚÀÇ ±â°ü ¸ð¾ç°ú Å©±â¿¡ ÀûÀÀÇÏ¿© ±âµµ ÇùÂøÀ» Áï°¢ÀûÀ¸·Î ¿ÏÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â°ü ÇùÂø, ±â°ü ¿¬È­Áõ, ±â°ü »ð°ü ÈÄ ¼Õ»ó µîÀÇ »óŸ¦ °ü¸®ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇϸç, ȯÀÚÀÇ »óÅ¿¡ µû¶ó ÀϽÃÀû ¶Ç´Â ¿µ±¸ÀûÀÎ Àúħ½ÀÀû ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. ±â°ü ½ºÅÙÆ®´Â ÀÀ±Þ ¹× °èȹµÈ ÀÇ·á °³ÀÔ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ¼öÇàÇÏ¿© ±âµµ Æó¼â ȯÀÚÀÇ È£Èí ±â´ÉÀ» °³¼±ÇÏ°í »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù.

¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), Æó¾Ï, ±â°üÇãÅ» µî ±âµµ °ü¸®°¡ ÇÊ¿äÇÑ È£Èí±â Áúȯ ¹× ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ±â°ü ½ºÅÙÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±â°ü ½ºÅÙÆ®´Â ÀÀ±Þ»óȲ¿¡¼­ ±âµµÀÇ °³ÅëÀ» ȸº¹Çϱâ À§ÇØ ½Å¼ÓÇÏ°Ô ¹èÄ¡ÇÒ ¼ö ÀÖ¾î ÁßȯÀÚ Ä¡·á¿¡ ÇʼöÀûÀÎ µµ±¸°¡ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁøÇ༺ Æó¾Ï ȯÀÚÀÇ ¿ÏÈ­ ¼Ö·ç¼ÇÀ¸·Î »ç¿ëµÇ¾î È£Èí°ï¶õ(È£Èí°ï¶õ)°ú °°Àº Áõ»óÀ» ¿ÏÈ­Çϰí Àü¹ÝÀûÀΠȣÈí ´É·ÂÀ» Çâ»ó½Ãŵ´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿¡ µû¶ó È£Èí±â ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ±â°ü ½ºÅÙÆ® ¼ö¿ä Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±â°ü ½ºÅÙÆ®´Â ´Ù¾çÇÑ Å©±â, ÀçÁú, µðÀÚÀÎÀÇ ½ºÅÙÆ®¸¦ »ç¿ëÇÒ ¼ö ÀÖ¾î ȯÀÚ °³°³ÀÎÀÇ Çʿ信 µû¶ó ¸ÂÃã Ä¡·á°¡ °¡´ÉÇϸç, Çö´ë È£Èí±â Ä¡·á¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

±â°ü ½ºÅÙÆ®´Â ¾î¶»°Ô ±âµµ °ü¸®¿Í ȯÀÚ ¿¹Èĸ¦ °³¼±Çմϱî?

±â°ü ½ºÅÙÆ®´Â ÁßÁõ ±âµµÆó¼â ȯÀÚ¸¦ Áï°¢ÀûÀ̰í È¿°úÀûÀ¸·Î ¿ÏÈ­Çϱ⠶§¹®¿¡ ±Þ¼º ¹× ¸¸¼º È£Èí±â °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ ½ºÅÙÆ®´Â Á¼¾ÆÁø ±â°üÀ» ¹°¸®ÀûÀ¸·Î È®Àå½ÃÄÑ ±â·ù¸¦ °³¼±Çϰí È£Èí ºÎÀüÀÇ À§ÇèÀ» ÁÙÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ½Ç¸®ÄÜ ±â°ü ½ºÅÙÆ®´Â ƯÈ÷ ¾ç¼º ±â°ü ÇùÂøÀ̳ª ±â°ü ¿¬È­Áõ ȯÀÚ¿¡¼­ ±â°ü ³»°­À» À¯ÁöÇÏ´Â µ¥ È¿°úÀûÀÎ °­¼º ±¸Á¶¸¦ Á¦°øÇÕ´Ï´Ù. ¹Ý¸é, ´ÏƼ³î°ú °°Àº ±Ý¼Ó ±â¹Ý ½ºÅÙÆ®´Â ÀÚ±â È®À强°ú À¯¿¬¼ºÀ» °®µµ·Ï ¼³°èµÇ¾î ±â°ü ÇØºÎÇÐÀû ±¸Á¶¿¡ ÀûÀÀÇÏ¿© ¾Ç¼º ÇùÂøÀ̳ª ±â°ü ÇãÅ»ÀÌ ¹Ýº¹µÇ´Â °æ¿ì Àå±âÀûÀÎ ¾ÈÁ¤¼ºÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ½ºÅÙÆ®´Â ÃÖ¼Ò Ä§½ÀÀû ±â°üÁö°æÀ¸·Î »ðÀÔÇÒ ¼ö ÀÖ¾î Å« ¼ö¼úÀ̳ª ±×¿¡ µû¸¥ ÇÕº´ÁõÀÌ ÇÊ¿ä ¾ø¾î °íÀ§Ç豺 ȯÀÚ¿¡°Ô ÀûÇÕÇÕ´Ï´Ù.

±â°ü ½ºÅÙÆ®°¡ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â ´É·ÂÀº ÀÀ±Þ ÀÇ·á¿¡¼­ ¿ÏÈ­ Ä¡·á¿¡ À̸£±â±îÁö ´Ù¾çÇÑ ÀÓ»ó Àå¸é¿¡¼­ »ç¿ëµÇ´Â °ÍÀ» º¸¸é ¾Ë ¼ö ÀÖ½À´Ï´Ù. ½ºÅÙÆ®´Â ±â·ù¸¦ ȸº¹½Ãų »Ó¸¸ ¾Æ´Ï¶ó õ¸í, ±âħ, È£Èí°ï¶õ°ú °°Àº Áõ»óÀ» ¿ÏÈ­½ÃÄÑ È¯ÀÚÀÇ Æí¾ÈÇÔ°ú ÀÏ»ó »ýȰ ±â´ÉÀ» Å©°Ô Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ, ½ºÅÙÆ® »ðÀÔ¼úÀº ħ½ÀÀûÀÎ ¼ö¼ú¿¡ ºñÇØ ȸº¹ÀÌ ºü¸¥ °æ¿ì°¡ ¸¹¾Æ ÀÔ¿ø ±â°£À» ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾Ç¼º Áúȯ ȯÀÚ¿¡°Ô ±â°ü ½ºÅÙÆ®´Â ¿ÏÈ­ Ä¡·á µµ±¸·Î ÀÛ¿ëÇÏ¿© È£Èí °ï¶õÀ» ¿ÏÈ­Çϰí ÁøÇ༺ ÁúȯÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ±â°ü ½ºÅÙÆ®ÀÇ ¿ªÇÒÀº ¼ö¼úÀÌ ÀûÇÕÇÏÁö ¾ÊÀº ȯÀÚÀÇ Ä¡·á °ø¹éÀ» ¸Þ¿ì´Â °ÍÀ¸·Î, ±âµµ °ü¸®¿¡¼­ ±â°ü ½ºÅÙÆ®ÀÇ Á߿伺À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. ±â°ü ½ºÅÙÆ®´Â ÀûÀýÇÑ Âø¿ë°ú ÈÄ¼Ó °ü¸®¸¦ ÅëÇØ Àå±âÀûÀ¸·Î ±âµµÀÇ ¾ÈÁ¤¼ºÀ» À¯ÁöÇϰí, ÁßÀç ºóµµ¸¦ ÁÙÀ̸ç, Àü¹ÝÀûÀΠȣÈí±â °Ç°­À» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù.

±â¼ú ¹ßÀüÀº ±â°ü ½ºÅÙÆ®ÀÇ °³¹ßÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

±â¼úÀÇ ¹ßÀüÀº ±â°ü ½ºÅÙÆ®ÀÇ µðÀÚÀÎ, Àç·á ¹× Àü´Þ ½Ã½ºÅÛ¿¡ Å« Çõ½ÅÀ» °¡Á®¿ÔÀ¸¸ç, ȯÀÚ¿¡°Ô ´õ È¿°úÀûÀÌ°í ¾ÈÀüÇÑ ±â°ü ½ºÅÙÆ®¸¦ Á¦°øÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÁÖ¿ä Çõ½Å Áß Çϳª´Â Ç׿°ÁõÁ¦³ª È­Çпä¹ýÁ¦¿Í °°Àº ¾à¹°À» ±â°üÀ¸·Î Á÷Á¢ ¹æÃâÇÏ´Â ¾à¹° ¿ëÃ⼺ ±â°ü ½ºÅÙÆ®ÀÇ °³¹ßÀÔ´Ï´Ù. ÀÌ ½ºÅÙÆ®´Â ±âµµÀÇ °³Å뼺À» À¯ÁöÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¿°ÁõÀ» °ü¸®Çϰí Á¾¾çÀÇ À缺ÀåÀ» ¹æÁöÇÏ¿© ÀæÀº ½ºÅÙÆ® ±³Ã¼ ¹× Ãß°¡ °³ÀÔÀÇ Çʿ伺À» ÁÙ¿©ÁÝ´Ï´Ù. ½ºÅÙÆ® ¼³°è¿¡ »ýºÐÇØ¼º Àç·á¸¦ ÅëÇÕÇÏ´Â °Íµµ Áß¿äÇÑ ¹ßÀüÀ¸·Î, ÀϽÃÀûÀÎ ±âµµ ÁöÁö·ÂÀ» Á¦°øÇÏ°í ±â°ü Á¶Á÷ÀÌ ¾ÈÁ¤µÇ¸é Á¡Â÷ ºÐÇØµÇ¾î Àå±âÀûÀÎ ÇÕº´Áõ À§Çè°ú Á¦°Å ÀýÂ÷ÀÇ Çʿ伺À» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ, 3D ÇÁ¸°ÆÃ ¹× ȯÀÚº° ¸ðµ¨¸µ°ú °°Àº ¿µ»ó ±â¼úÀÇ ¹ßÀüÀ¸·Î °³º° ȯÀÚÀÇ ÇØºÎÇÐÀû ±¸Á¶¿¡ ¸Â´Â ¸ÂÃãÇü ±â°ü ½ºÅÙÆ®¸¦ Á¦ÀÛÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ °³ÀÎÈ­´Â ½ºÅÙÆ®ÀÇ ÀûÇÕ¼ºÀ» Çâ»ó½Ã۰í, À̵¿ÀÇ À§ÇèÀ» ÁÙÀ̸ç, ȯÀÚÀÇ Àü¹ÝÀûÀÎ Æí¾ÈÇÔÀ» Çâ»ó½Ãŵ´Ï´Ù. ±â°üÁö°æ °Ë»ç Áß ½ºÅÙÆ®¸¦ ½±°Ô ¹èÄ¡Çϰí Àç¹èÄ¡ÇÒ ¼ö ÀÖµµ·Ï Àúħ½ÀÀû Àü´Þ ½Ã½ºÅÛµµ ¹ßÀüÇß½À´Ï´Ù. ¸Þ¸ð¸® Ư¼ºÀ» °¡Áø ´ÏƼ³î Çձݰú °°Àº ½ºÅÙÆ® Àç·áÀÇ Çõ½ÅÀº ½ºÅÙÆ®ÀÇ À¯¿¬¼ºÀ» Çâ»ó½Ã۰í È£Èí Áß ±âµµÀÇ µ¿Àû º¯È­¿¡ ´ëÇÑ ÀûÀÀ·ÂÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. ½ºÅÙÆ®¿¡ Ç×±Õ ÄÚÆÃÀ» Àû¿ëÇÏ´Â °Íµµ °³¹ß ºÐ¾ß Áß Çϳª·Î, Àå±â°£ ½ºÅÙÆ® »ðÀÔ¿¡ µû¸¥ °¨¿° À§ÇèÀ» ÁÙÀÌ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû Áøº¸´Â ±â°ü ½ºÅÙÆ®ÀÇ ¼º´ÉÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ÀáÀçÀûÀÎ ¿ëµµ¸¦ È®ÀåÇÏ¿© º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀÎ ´Ù¾çÇÑ ±âµµ »óÅÂÀÇ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

±â°ü ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

±â°ü ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ½ºÅÙÆ® ±â¼úÀÇ ¹ßÀü µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖÀ¸¸ç, COPD, Æó¾Ï, ±â°üÁö ÇùÂø°ú °°Àº È£Èí±â ÁúȯÀÌ º¸ÆíÈ­µÊ¿¡ µû¶ó È¿°úÀûÀÎ ±âµµ °ü¸® ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Çʿ伺ÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±â°ü ½ºÅÙÆ®´Â ¼ö¼ú¿¡ ´ëÇÑ ´ú ħ½ÀÀûÀÎ ´ë¾ÈÀ¸·Î, ƯÈ÷ °í·ÉÀÇ È¯ÀÚ³ª ÇÕº´ÁõÀÌ ÁøÇàµÈ ȯÀڵ鿡°Ô ¸Å·ÂÀûÀÎ Ä¡·á¹ýÀÔ´Ï´Ù. È£Èí±â Áúȯ¿¡ Ãë¾àÇÑ °í·ÉÈ­ »çȸ·Î ÀÎÇØ Àå±âÀûÀΠȣÈí±â Ä¡·áÀÇ ÀÏȯÀ¸·Î ±â°ü ½ºÅÙÆ®¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÀ±Þ½Ç°ú ÁßȯÀڽǿ¡¼­ ½ºÅÙÆ® »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ±Þ¼º ±âµµ °ü¸®¿¡¼­ ½ºÅÙÆ®ÀÇ Á߿伺ÀÌ ºÎ°¢µÇ¸é¼­ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¾à¹° ¿ëÃ⼺ ¹× »ýºÐÇØ¼º µî ½ºÅÙÆ® ¼³°èÀÇ ¹ßÀüÀ¸·Î Ä¡·á ¹× ¿ÏÈ­ Ä¡·á¿¡¼­ ±â°ü ½ºÅÙÆ®ÀÇ »ç¿ë ¹üÀ§°¡ ³Ð¾îÁö°í ÀÖ½À´Ï´Ù. »õ·Î¿î ½ºÅÙÆ® ¸ðµ¨¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΰú ÇÔ²² ¸¹Àº ±¹°¡¿¡¼­ °³¼±µÈ »óȯ Á¤Ã¥°ú ÇÔ²² ÀÇ·á ¼­ºñ½º Á¦°ø¾÷üµéÀÌ ±âµµ Æó¼â¿¡ ´ëÇÑ Ç¥ÁØ Ä¡·á¹ýÀ¸·Î ½ºÅÙÆ® »ðÀÔ¼úÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÅÈï ½ÃÀåÀÇ ÀÇ·á ÀÎÇÁ¶ó È®´ë¿Í °í±Þ ±âµµ °ü¸®¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ±â°ü ½ºÅÙÆ® Á¦Á¶¾÷ü¿¡ »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ¿ø°Ý ÀÇ·á¿Í ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ ºÎ»óÀ¸·Î ±â°ü ½ºÅÙÆ®ÀÇ Ã¤ÅÃÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ÈÄ¼Ó Ä¡·á¸¦ ¿ëÀÌÇÏ°Ô Çϰí ÀáÀçÀûÀÎ ÇÕº´ÁõÀ» Àû½Ã¿¡ °ü¸®ÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ±â¼ú Çõ½ÅÀ¸·Î ½ºÅÙÆ®ÀÇ È¿°ú, ȯÀÚ ¾ÈÀü, ½Ã¼úÀÇ ÆíÀǼºÀÌ Áö¼ÓÀûÀ¸·Î °³¼±µÊ¿¡ µû¶ó ±â°ü ½ºÅÙÆ® ½ÃÀåÀº ´õ ³ªÀº È£Èí±â Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Àü ¼¼°è ¼ö¿ä·Î ÀÎÇØ Áö¼ÓÀûÀÎ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù.

ºÎ¹®

¼ÒÀç(±Ý¼Ó, ÇÃ¶ó½ºÆ½, ±âŸ ¼ÒÀç)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇÕ´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Tracheal Stents Market to Reach US$219.5 Million by 2030

The global market for Tracheal Stents estimated at US$146.7 Million in the year 2024, is expected to reach US$219.5 Million by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Metal, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$154.2 Million by the end of the analysis period. Growth in the Plastic segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$38.2 Million While China is Forecast to Grow at 10.3% CAGR

The Tracheal Stents market in the U.S. is estimated at US$38.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$51.8 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Tracheal Stents Market - Key Trends & Drivers Summarized

What Are Tracheal Stents & Why Are They Crucial for Airway Management?

Tracheal stents are tubular medical devices designed to maintain an open airway in patients with tracheal obstructions or stenosis. Made from materials such as silicone, nitinol, or other biocompatible alloys, tracheal stents are used to stabilize the trachea and ensure unobstructed airflow in cases where the airway is narrowed due to tumors, trauma, inflammation, or congenital abnormalities. The stents can be either self-expanding or balloon-expandable, allowing them to adapt to the shape and size of the patient’s trachea, providing immediate relief from airway constriction. They are crucial in managing conditions such as tracheal stenosis, tracheomalacia, and post-intubation injuries, offering a minimally invasive solution that can be temporary or permanent depending on the patient’s condition. Tracheal stents play a vital role in both emergency and planned medical interventions, improving respiratory function and enhancing the quality of life for patients with airway obstructions.

The increasing prevalence of respiratory diseases and conditions requiring airway management, such as chronic obstructive pulmonary disease (COPD), lung cancer, and tracheal collapse, has driven demand for tracheal stents. In emergency settings, tracheal stents can be rapidly deployed to restore airway patency, making them essential tools in critical care. They are also used as palliative solutions in patients with advanced lung cancer, providing relief from symptoms like dyspnea (shortness of breath) and improving overall respiratory capacity. As the global population ages, the incidence of respiratory diseases is rising, contributing to the growing demand for tracheal stents. The availability of stents in various sizes, materials, and designs enables tailored treatments that cater to individual patient needs, making tracheal stents indispensable in modern respiratory care.

How Do Tracheal Stents Improve Airway Management & Patient Outcomes?

Tracheal stents offer immediate and effective relief for patients with severe airway obstructions, making them critical in both acute and chronic respiratory management. These stents work by physically propping open the narrowed segment of the trachea, allowing for better airflow and reducing the risk of respiratory failure. Silicone tracheal stents, for instance, provide a rigid structure that is effective in maintaining the tracheal lumen, especially in patients with benign tracheal stenosis or tracheomalacia. On the other hand, metal-based stents, such as those made from nitinol, are designed to be self-expanding and flexible, adapting to the anatomy of the trachea and providing long-term stability in cases of malignant stenosis or recurring tracheal collapse. These stents can be placed using minimally invasive bronchoscopy, reducing the need for extensive surgery and associated complications, making them suitable for high-risk patients.

The ability of tracheal stents to improve patient outcomes is evident in their use across a variety of clinical settings, from emergency care to palliative therapy. In addition to restoring airflow, these stents help alleviate symptoms such as wheezing, coughing, and difficulty breathing, significantly improving patients' comfort and daily function. They also reduce hospital stay duration, as stenting often leads to quicker recovery compared to more invasive surgical procedures. For patients with malignant conditions, tracheal stents can serve as palliative care tools, offering relief from respiratory distress and enhancing quality of life during advanced stages of disease. The role of tracheal stents in bridging treatment gaps for patients who are not candidates for surgery further underscores their importance in airway management. With proper placement and follow-up care, tracheal stents can provide long-lasting airway stability, reducing the frequency of interventions and improving overall respiratory health.

How Are Technological Advancements Shaping the Development of Tracheal Stents?

Technological advancements have led to significant innovations in the design, materials, and delivery systems of tracheal stents, making them more effective and safer for patients. One of the major innovations is the development of drug-eluting tracheal stents, which release medications such as anti-inflammatory drugs or chemotherapeutic agents directly into the trachea. These stents not only maintain airway patency but also help manage inflammation and prevent tumor regrowth, reducing the need for frequent stent replacements and additional interventions. The integration of biodegradable materials into stent designs is another significant advancement, offering temporary airway support that gradually degrades once the tracheal tissue stabilizes, minimizing the risk of long-term complications and the need for removal procedures.

Additionally, advances in imaging technologies, such as 3D printing and patient-specific modeling, have enabled the creation of custom-fit tracheal stents tailored to individual patient anatomy. This personalization improves stent fit, reduces migration risks, and enhances overall patient comfort. Minimally invasive delivery systems have also evolved, allowing for easier deployment and repositioning of stents during bronchoscopy. Innovations in stent materials, such as nitinol alloys with memory properties, have improved stent flexibility, allowing for better adaptation to dynamic changes in airway size during breathing. The incorporation of anti-microbial coatings on stents is another area of development, aimed at reducing infection risks associated with prolonged stent placement. These technological advancements not only enhance the performance of tracheal stents but also expand their potential applications, making them safer and more effective in treating a wider range of airway conditions.

What Factors Are Driving Growth in the Tracheal Stents Market?

The growth in the tracheal stents market is driven by several factors, including the rising prevalence of respiratory diseases, increased demand for minimally invasive treatments, and advancements in stent technology. As respiratory diseases such as COPD, lung cancer, and tracheal stenosis become more common, the need for effective airway management solutions has grown significantly. Tracheal stents offer a less invasive alternative to surgery, making them particularly appealing for elderly patients and those with advanced comorbidities. The aging global population, which is more susceptible to respiratory ailments, further fuels demand for tracheal stents as part of long-term respiratory care. Moreover, the increasing use of stents in emergency settings and critical care has highlighted their importance in acute airway management, contributing to market growth.

Advancements in stent design, such as drug-eluting and biodegradable options, have broadened the scope of tracheal stents in both therapeutic and palliative care. Regulatory approvals of new stent models, combined with improved reimbursement policies in many countries, have also encouraged healthcare providers to adopt stenting as a standard treatment for airway obstructions. Additionally, the expansion of healthcare infrastructure in emerging markets, coupled with growing awareness about advanced airway management, is creating new opportunities for tracheal stent manufacturers. The rise of telemedicine and remote patient monitoring has further supported the adoption of tracheal stents, as these technologies facilitate follow-up care and ensure timely management of potential complications. As innovations continue to enhance stent efficacy, patient safety, and procedural ease, the tracheal stents market is poised for sustained growth, driven by the need for better respiratory care solutions worldwide.

SCOPE OF STUDY:

The report analyzes the Tracheal Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Material (Metal, Plastic, Other Materials)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â